ERBB2 and breast cancer: Deletion of Gpr109a, a receptor activated by butyrate, increased tumor incidence and activated early onset of mammary tumorigenesis in MMTV-Neu mouse model of spontaneous breast cancer, supporting the hypothesis that GPR109A was a tumor suppressor in mammary glands [104].